29 Jan 2008 - Galapagos NV announced achievement of a milestone under its alliance agreement in rheumatoid arthritis with Janssen Pharmaceutica NV. The milestone triggered a cash payment of EUR 3.4 million to Galapagos.
On 24 October 2007, Galapagos announced an alliance agreement with Janssen providing it with option rights to acquire worldwide, commercial licenses to novel small-molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis (RA) therapeutic targets. The milestone announced today was due to the achievement of a milestone with respect to the GT146 program.
 |
www.bionity.com/news/e/77065 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/77065 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |